Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Moleculin Biotech (MBRX)
NASDAQ:MBRX
Holding MBRX?
Track your performance easily
MBRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.12 - $15.76
Previous Close$2.44
Volume31.47K
Average Volume (3M)31.85K
Market Cap
$6.97M
Enterprise Value-$3.46M
Total Cash (Recent Filing)$10.85M
Total Debt (Recent Filing)$420.00K
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Nov 08, 2024EPS Estimate
-$2.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.66
Shares Outstanding2,840,000
10 Day Avg. Volume17,793
30 Day Avg. Volume31,851
Standard Deviation0.20
R-Squared0.22
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.37
Price to Sales (P/S)577.47
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-287.99
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Moleculin Biotech News
PremiumCompany Announcements
Moleculin Biotech to Announce Q3 Results in NovemberPremiumCompany Announcements
Moleculin Biotech’s Annual Meeting Decisions and Elections
PremiumCompany Announcements
Moleculin Biotech Highlights Annamycin’s AML Treatment Potential
PremiumCompany Announcements
Moleculin Biotech Hosts Virtual AML KOL Event and Trial Update
PremiumCompany Announcements
Moleculin Biotech Releases Updated Corporate Presentation
Ownership Overview
3.20% Insiders
3.58% Mutual Funds
0.12% Other Institutional Investors
90.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MBRX FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $2.12 and its highest was $15.76 in the past 12 months.
What is Moleculin Biotech’s market cap?
Currently, no data Available
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Nov 08, 2024 which is 2 days ago.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on Aug 14, 2024. The company reported -$1.7 earnings per share for the quarter, beating the consensus estimate of -$2.51 by $0.81.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Overvalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -$2.44.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 2,844,527 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$1.7 in its last earnings report, beating expectations of -$2.51. Following the earnings report the stock price went up 6.383%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in MBRX
---
Moleculin Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.16%
12-Months-Change
Fundamentals
Return on Equity
-86.82%
Trailing 12-Months
Asset Growth
-45.72%
Trailing 12-Months
Company Description
Moleculin Biotech
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.
---
MBRX Earnings Call
Q1 2024
0:00 / 0:00
---
MBRX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Brainstorm Cell Therapeutics
―
Cellectar Biosciences
―
Bio-Path Holdings
―
Eloxx Pharmaceuticals
―
Best Analysts Covering MBRX
1 Year
1 Year Success Rate
1/9 ratings generated profit
1 Year Average Return
-47.13%
reiterated a buy rating 5 months ago
Copying Jonathan Aschoff's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -47.13% per trade.
---